Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining the report for the IDH1 & IDH2 Gene Mutations Test is 14 days.

What are the prerequisites for the test IDH1 & IDH2 Gene Mutations Test

  • There are no specific prerequisites for the IDH1 & IDH2 Gene Mutations Test.
  • However, it is recommended to consult with a healthcare provider or genetic counselor before undergoing the test.
  • Patients may be required to provide a blood or tissue sample for the test.
  • Patients should also disclose any relevant medical history or medications they are currently taking.

What are the measure values for the test IDH1 & IDH2 Gene Mutations Test

  • IDH1 Gene Mutations Test:
    • Measure Value: Positive or Negative
    • Positive Result: Presence of IDH1 gene mutation
    • Negative Result: Absence of IDH1 gene mutation
  • IDH2 Gene Mutations Test:
    • Measure Value: Positive or Negative
    • Positive Result: Presence of IDH2 gene mutation
    • Negative Result: Absence of IDH2 gene mutation

What does this test IDH1 & IDH2 Gene Mutations Test identify?

  • The IDH1 & IDH2 Gene Mutations Test identifies mutations in the isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) genes.
  • These mutations are commonly found in various types of cancer, including gliomas, acute myeloid leukemia (AML), and chondrosarcoma.
  • Identifying these mutations can help in the diagnosis, prognosis, and treatment planning for patients with cancer.

Why is this test IDH1 & IDH2 Gene Mutations Test taken?

The IDH1 & IDH2 Gene Mutations Test is taken to identify mutations in the isocitrate dehydrogenase 1 and 2 genes. These mutations are commonly found in certain types of cancers, such as gliomas, acute myeloid leukemia, and chondrosarcomas.

Identifying these mutations can help in determining the prognosis of the cancer, guiding treatment decisions, and monitoring the response to treatment. Additionally, some targeted therapies have been developed specifically for cancers with IDH1 or IDH2 mutations, making this test important for personalized treatment approaches.

No FAQs available.

Customer Google Rating